- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Piramal Pharma reported latest quarter revenue of ₹1,934 Cr (-1% YoY). While CDMO saw a 6% decline, excluding one product's destocking, it achieved mid-teen growth with improved overseas profitability. Consumer Healthcare surged 15% to ₹302 Cr, driven by Power Brands and e-commerce. Complex Hospital Generics grew 1% to ₹637 Cr, securing USFDA approval for its Digwal site. EBITDA dropped 26% to ₹165 Cr (9% margin). The company is investing ₹751.5 Cr in US capacity expansion to bolster integrated ADC capabilities.